

DOCKET: CU-2642

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Petr Jakovlevich Gaponyuk et al. )  
SERIAL NO: 09/936,470 ) Group Art Unit: 1646  
FILED: December 18, 2001 ) Examiner: Ruixiang Li  
TITLE: ANTIVIRAL AGENT IN THE FORM  
OF NOSE DROPS

THE ASSISTANT COMMISSIONER FOR PATENTS  
Washington, D.C. 20231

**CLEAN VERSION OF AMENDED ABSTRACT**

C7  
The present invention can be used in pharmacology specifically in the preparation of interferon-containing compositions, which are capable of conserving their biological activity and can be administrated intranasally, e.g. in the preparation of nasal drops. This invention essentially refers to an antiviral agent in the form of nasal drops that contains a genetically engineered alpha, beta or gamma interferon with a viscosity of  $(1.1 - 30.0) * 10$  Pascal-second, a biocompatible polymer and a buffer mixture. The agent may further include an antioxidant, and the ingredients are contained in the following amounts per ml buffer mixture: 1,000 to 5,000 IU of genetically engineered interferon; 0.005 to 0.714 g of biocompatible polymer; and 0.0001 to 0.0008 g of an antioxidant. TRILON B® (disodium salt of EDTA) is used as the antioxidant, whereas polyvinylpyrrolidone and/or polyethylene oxide is (are) used as the biocompatible polymer(s) at polyvinylpyrrolidone/polyethylene oxide ratio of 1:1 - 50.